HUTCHMED (China) (HMDCF) Total Current Liabilities (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Total Current Liabilities came in at $275.2 million in Q2 2026, down 19.61% year-over-year from $342.3 million in Q2 2025, and down 12.85% quarter-over-quarter from $315.8 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Total Current Liabilities (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Total Current Liabilities for 12 consecutive years, with $275.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Current Liabilities fell 19.61% year-over-year to $275.2 million in Q2 2026; TTM through Jun 2026 was $275.2 million, a 19.61% decrease from a year earlier, with the FY2025 full-year figure at $315.8 million, changed N/A from the prior year.
- Total Current Liabilities was $275.2 million for Q2 2026 at HUTCHMED (China), down from $315.8 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $373.3 million in Q2 2024 and troughed at $275.2 million in Q2 2026.
- A 5-year average of $331.9 million and a median of $340.9 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities gained 29.93% in 2022 and dropped 19.61% in 2026, its largest moves.
- Over 5 years, Total Current Liabilities stood at $353.9 million in 2022, then slipped by 3.68% to $340.9 million in 2023, then gained by 9.51% to $373.3 million in 2024, then declined by 15.41% to $315.8 million in 2025, then slipped by 12.85% to $275.2 million in 2026.
- The last three Total Current Liabilities figures came in at $275.2 million (Q2 2026), $315.8 million (Q4 2025), and $342.3 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | 283.60 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 275.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 275.21 Mn |
| Dec 31, 2025 | 315.78 Mn |
| Jun 30, 2025 | 342.35 Mn |
| Jun 30, 2024 | 373.29 Mn |
| Jun 30, 2023 | 340.86 Mn |
| Dec 31, 2022 | 353.90 Mn |
| Jun 30, 2022 | 321.86 Mn |
| Dec 31, 2021 | 311.66 Mn |
| Jun 30, 2021 | 247.72 Mn |
| Mar 31, 2021 | 188.52 Mn |
| Dec 31, 2020 | 158.40 Mn |
| Jun 30, 2020 | 119.39 Mn |
| Dec 31, 2019 | 113.10 Mn |
| Sep 30, 2019 | 105.35 Mn |
| Jun 30, 2019 | 110.61 Mn |
| Mar 31, 2019 | 101.33 Mn |
| Dec 31, 2018 | 85.48 Mn |
| Jun 30, 2018 | 84.58 Mn |
| Dec 31, 2017 | 104.60 Mn |
| Jun 30, 2017 | 96.84 Mn |